New hope for PNH: experimental drug aims to outdo soliris
NCT ID NCT05646563
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called NM8074 in 12 adults with paroxysmal nocturnal hemoglobinuria (PNH) who are already taking Soliris. PNH is a rare blood disorder where the immune system destroys red blood cells, causing anemia and fatigue. NM8074 is designed to block a different part of that immune attack, and researchers want to see if it is safe and can control the disease as well as or better than Soliris alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
NM8074 (a lab-made antibody that blocks part of the immune system's attack on blood cells)
What this could lead to
If it works, NM8074 could offer PNH patients a new treatment option that may be more convenient or have fewer side effects than current therapy.
What could go wrong
This is a small, early-phase trial with only 12 participants, so results may not apply to everyone. The drug is new and its safety and effectiveness are not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAROXYSMAL NOCTURNAL HEMOGLOBINURIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••